ORIC-114 with amivantamab for EGFR exon 20 insertion lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental pill (ORIC-114) combined with a targeted injection (amivantamab) for a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It aims to see if the combination shrinks tumors or delays growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must have spread to other parts of the body (metastatic) and have a specific mutation called EGFR exon 20 insertion.
- You must not have received prior immunotherapy for your cancer.
- You must be willing and medically able to have a biopsy before starting treatment.
- You must have measurable tumors on a CT scan or MRI.
- You must be in good physical condition (able to do daily activities) with no major organ problems.
- You must not have had an allergic lung reaction to drugs or radiation in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.